Diagnostic Performance of Immunohistochemistry Compared to Molecular Techniques for Microsatellite Instability and p53 Mutation Detection in Endometrial Cancer
暂无分享,去创建一个
V. Bours | F. Goffin | L. Seidel | L. Habran | F. Kridelka | K. Delbecque | C. Gennigens | A. Kakkos | S. Streel | N. Leroi | C. Pleyers | É. Gonne | Alixe Salmon | Adriane Dheur
[1] P. Izzo,et al. Hereditary Colorectal Cancer: State of the Art in Lynch Syndrome , 2022, Cancers.
[2] A. Talhouk,et al. O005/#638 ProMisE-2: a one step DNA-based endometrial cancer molecular classifier , 2022, Oral Abstracts (Regular and Late-Breaking Submission).
[3] A. Mariani,et al. A novel algorithm to implement the molecular classification according to the new ESGO/ESTRO/ESP 2020 guidelines for endometrial cancer , 2022, International Journal of Gynecological Cancer.
[4] J. McAlpine,et al. Molecular classification in endometrial cancer: Opportunities for precision oncology in a changing landscape , 2022, Cancer.
[5] M. Fassan,et al. Biomarker characterization in endometrial cancer in Italy: first survey data analysis , 2022, Pathologica.
[6] P. Pollock,et al. p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial , 2022, Modern Pathology.
[7] M. Fassan,et al. Current Prognostic and Predictive Biomarkers for Endometrial Cancer in Clinical Practice: Recommendations/Proposal from the Italian Study Group , 2022, Frontiers in Oncology.
[8] C. Luchini,et al. Artificial Intelligence for Predicting Microsatellite Instability Based on Tumor Histomorphology: A Systematic Review , 2022, International journal of molecular sciences.
[9] A. Scarpa,et al. Artificial intelligence in oncology: current applications and future perspectives , 2021, British Journal of Cancer.
[10] Qi Wang,et al. Variations in incidence and mortality rates of endometrial cancer at the global, regional, and national levels, 1990-2019. , 2021, Gynecologic oncology.
[11] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[12] M. Buisine,et al. Diagnosis of Lynch Syndrome and Strategies to Distinguish Lynch-Related Tumors from Sporadic MSI/dMMR Tumors , 2021, Cancers.
[13] K. Claes,et al. Comparison of microsatellite instability detection by immunohistochemistry and molecular techniques in colorectal and endometrial cancer , 2021, Scientific Reports.
[14] J. McAlpine,et al. The emerging role of molecular pathology in directing the systemic treatment of endometrial cancer , 2021, Therapeutic advances in medical oncology.
[15] Cyrus Chargari,et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma , 2020, International Journal of Gynecological Cancer.
[16] H. Putter,et al. Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] L. Insabato,et al. Diagnostic accuracy of p53 immunohistochemistry as surrogate of TP53 sequencing in endometrial cancer. , 2020, Pathology, research and practice.
[18] L. Hoang,et al. Interpretation of p16, p53 and mismatch repair protein immunohistochemistry in gynaecological neoplasia , 2020 .
[19] L. Insabato,et al. Diagnostic Accuracy of Immunohistochemistry for Mismatch Repair Proteins as Surrogate of Microsatellite Instability Molecular Testing in Endometrial Cancer , 2020, Pathology & Oncology Research.
[20] Mohamed A. Elgharib,et al. The Use of Artificial Intelligence and Deep Machine Learning in Oncologic Histopathology. , 2020, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.
[21] E. Pasmant,et al. Identification of TP53 mutated group using a molecular and immunohistochemical classification of endometrial carcinoma to improve prognostic evaluation for adjuvant treatments , 2020, International Journal of Gynecological Cancer.
[22] T. Bosse,et al. Incorporation of molecular characteristics into endometrial cancer management , 2019, Histopathology.
[23] C. Gilks,et al. Clinicopathological and molecular characterisation of ‘multiple‐classifier’ endometrial carcinomas , 2019, The Journal of pathology.
[24] M. Köbel,et al. p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies , 2019, The Journal of pathology.
[25] Mitsuhiro Nakamura,et al. The Association and Significance of p53 in Gynecologic Cancers: The Potential of Targeted Therapy , 2019, International journal of molecular sciences.
[26] S. Kamel‐Reid,et al. Heterogenous loss of mismatch repair (MMR) protein expression: a challenge for immunohistochemical interpretation and microsatellite instability (MSI) evaluation , 2018, The journal of pathology. Clinical research.
[27] M. Köbel,et al. Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility , 2018, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[28] A. Talhouk,et al. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[29] Y. Mizumoto,et al. Dual expression of immunoreactive estrogen receptor β and p53 is a potential predictor of regional lymph node metastasis and postoperative recurrence in endometrial endometrioid carcinoma , 2017, PloS one.
[30] N. Rosenfeld,et al. Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma , 2016, The journal of pathology. Clinical research.
[31] A. Talhouk,et al. Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas. , 2015, Gynecologic oncology.
[32] H. Mackay,et al. Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing , 2014, Cancer.
[33] Steven J. M. Jones,et al. Integrated genomic characterization of endometrial carcinoma , 2013, Nature.
[34] J. Shia,et al. Utility of Immunohistochemistry in Predicting Microsatellite Instability in Endometrial Carcinoma , 2007, The American journal of surgical pathology.
[35] A. Duval,et al. Quasimonomorphic Mononucleotide Repeats for High-Level Microsatellite Instability Analysis , 2004, Disease markers.
[36] A. Duval,et al. Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. , 2002, Gastroenterology.
[37] J. R. Landis,et al. The measurement of observer agreement for categorical data. , 1977, Biometrics.